SURMOUNT-MMO GLP1-RA for weight loss in patients without diabetes and increased cardiovascular risk. Enrollment to begin soon.
Evolve-MI (Amgen) Phase IV • Evolucumab + statin vs standard of care early after MI (STEMI/ACS NSTEMI). Open label
PREVAIL (New Amsterdam Pharma) Phase III • Obicetrapib (CETP inhibitor) vs placebo PO Daily for patients with ASCVD and LDL chol >70
Oceans(a) (Amgen) Phase III • Olparsiran vs standard of care early after treatment of Lipoprotein a (Lp(a)) in patgients with h/o MI or high risk patietns after PCI. Double blind placebo controlled study.
VICTORION-INCEPTION (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care for patients with recent acute coronary syndrome
ORION-4 (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo; examining outcomes in subjects with heart attack or stroke
VICTORION-INITIATE (Novartis)- Phase III • (*no longer enrolling*) Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care; assessing an “inclisiran-first” strategy in an ASCVD population
VESALIUS-CV (Amgen)- Phase III (*no longer enrolling*) • Evolocumab (monoclonal antibody, PCSK9 inhibitor) vs. Placebo; assessing the effect of evolocumab on major cardiovascular events in adults with prior heart attack or stroke
OCEANIC-AF (Bayer) Phase III • Asundexian (FXIa inhibitor) vs. apixaban for patients with atrial fibrillation.
RAPID (Milestone)- Phase III • Etripamil (novel intra-nasal verapamil analogue) vs. Placebo for the rapid termination of PSVT episodes
AZALEA (Anthos/TIMI)- Phase II (*no longer enrolling*) • Abelacimab (subcutaneous monoclonal antibody) vs. Rivaroxaban; assessing the bleeding profile of abelacimab in patients with AF with moderate-to-high risk of stroke o Paroxysmal Supraventricular Tachycardia
Expand TAVR II (Medtronic) • Evolut™ PRO and Evolut™ PRO+ Device in patients with moderate AS and Class II-III heart failure.
Optimize PRO (Medtronic) • (*no longer enrolling*) Evolut™ PRO and Evolut™ PRO+ Device Trial examining valve performance & procedural outcomes associated with an “optimized” TAVR (transcatheter aortic valve replacement) care pathway & post-TAVR conduction disturbance pathway
EXPAND G4 (Abbott) (*no longer enrolling*) • MitraClip device trial evaluating outcomes & characterizing trends in patient selection
DAPA ACT HF (AstraZeneca) • Phase IV o Dapagliflozin vs. Placebo; examining outcomes from in-hospital initiation in acute heart failure o Heart Failure with Preserved Ejection Fraction & Obesity
GPID SUMMIT (Eli Lilly)- Phase III • Tirzepatide (GIP & GLP-1 agonist) vs. Placebo in obese patients with chronic heart failure with preserved ejection fraction
RADIANCE II (Recor) • Paradise System device trial examining the effects of ultrasound renal denervation in subjects with medication-resistant hypertension